Resmed Inc

RMD

Equity

ISIN US7611521078 / Valor 321632

New York Stock Exchange, Inc (2024-11-20)

USD 241.55+1.44%

Resmed Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

ResMed Inc. is a global leader in the development and provision of innovative healthcare solutions, particularly focusing on the management and treatment of chronic diseases such as sleep apnea, COPD (Chronic Obstructive Pulmonary Disease), and other related conditions. The company distinguishes itself through its integration of digital health technologies and cloud-connected medical devices, which are designed to transform patient care by keeping individuals out of hospitals and enabling them to lead healthier lives. ResMed's offerings extend beyond individual patient care to include comprehensive software platforms aimed at supporting healthcare professionals and caregivers. These platforms facilitate the delivery of effective care in home or chosen care settings, thereby enhancing the quality of life for patients, reducing the burden of chronic diseases, and contributing to the reduction of healthcare costs. Operating in more than 140 countries, ResMed's approach to healthcare innovation emphasizes the importance of accessibility and efficiency in managing chronic health conditions on a global scale.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

ResMed Inc. reported a 9% increase in revenue for the fourth quarter of fiscal year 2024, reaching $1.2 billion. On a constant currency basis, revenue grew by 10%, driven by strong demand for sleep devices, masks, and the Software as a Service (SaaS) business.

Gross Margin Improvement

For the fourth quarter of fiscal year 2024, ResMed Inc. saw its gross margin improve by 350 basis points to 58.5%. The non-GAAP gross margin also increased by 330 basis points to 59.1%, attributed to reduced freight and manufacturing costs, higher average selling prices, and a favorable product mix.

Income from Operations

ResMed Inc.'s income from operations for the fourth quarter of fiscal year 2024 increased by 38%, with non-GAAP income from operations up by 30%. This significant growth was driven by strong sales and improved gross margins, alongside modest growth in operating expenses.

Dividend Increase

ResMed Inc. announced a 10% increase in its quarterly dividend, raising it to $0.53 per share for the fourth quarter of fiscal year 2024. The dividend will be payable on September 19, 2024, to shareholders of record as of August 15, 2024.

Operating Cash Flow

In the fourth quarter of fiscal year 2024, ResMed Inc. generated an operating cash flow of $440 million. This robust cash flow enabled the company to make debt repayments of $300 million and continue its capital management initiatives, including dividend payments and share repurchases.

Summarized from source with an LLMView Source

Key figures

59.7%1Y

-7.21%3Y

61.4%5Y

Performance

37.4%1Y

34.2%3Y

36.5%5Y

Volatility